Merck Life Science in India  announced the signing of a Memorandum of Understanding (MoU) with Aragen Life Sciences, a leading provider of R&D and manufacturing solutions in small molecules and biologics to the global life sciences industries. The MoU was signed by Aditya Sharma, Managing Director, Merck Life Science India, and Subodh Deshmukh, Chief Executive Officer, Aragen Life Sciences.

This strategic collaboration aims to bolster the supply of advanced equipment and cutting-edge technologies for monoclonal antibody (mAb) manufacturing and process development for novel modalities. By joining forces, Merck and Aragen are set to accelerate the clinical-to-commercial process timelines, enabling customers to develop the right molecules and efficiently scale up with comprehensive support.

The partnership underscores Merck's unwavering commitment to pioneering novel modalities and fostering early engagement in research and development with emerging biotechnology startups across India. Through this collaboration, both companies are poised to deliver enhanced solutions that will contribute to the global advancement of life sciences, particularly in the rapidly evolving field of biologics.

The collaboration between Merck and Aragen is expected to set new benchmarks in the life sciences industry, driving innovation and enabling the rapid advancement of novel therapies.